logo
Plus   Neg
Share
Email

Conatus Pharmaceuticals Inc. (CNAT) Is Surging On Novartis Agreement

Conatus Pharmaceuticals Inc. (CNAT) announced after the bell Monday that it has entered into an exclusive option, collaboration and license agreement with Novartis to develop and commercialize emricasan.

Conatus Pharmaceuticals has gapped open dramatically higher Tuesday morning and is now up 2.92 at $4.88 on strong volume. The stock has soared to a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT